Human and Animal Cell Bank, Iranian Biological Resource Center (IBRC), ACECR, Tehran, Iran.
Department of Oral and Maxillofacial Pathology, School of Dentistry, Tehran University of Medical Sciences, Tehran, Iran.
J Oral Pathol Med. 2018 Jul;47(6):575-582. doi: 10.1111/jop.12717. Epub 2018 May 8.
In recent decades, anti-angiogenic treatment strategy has been well described in cancer treatment. The anti-angiogenic activity of both bevacizumab and aflibercept has been researched on 10 previously established primary oral squamous cell carcinoma (OSCC) cells of an Iranian population with different levels of purity, in an attempt to find the most effective anti-angiogenic-targeted drug.
To investigate and compare the effect of bevacizumab and aflibercept on vascular endothelial growth factor (VEGF) secretion of 10 primary OSCC cells, cell proliferation and viability were assessed by ELISA and MTT assays. In addition, cell migration was studied using scratch assay.
The results showed that VEGF impressively expressed in all primary cancer cells. Although both drugs significantly reduced the secretion of VEGF, the effect of aflibercept was more prominent. Also, bevacizumab-treated cells migration was lower than the control group and the cells treated with aflibercept showed the lowest migration rate compared to bevacizumab and control groups.
The anti-angiogenic-targeted drugs, especially Af, might be effective in treatment of patients with OSCC in combination with conventional surgical treatments.
近几十年来，抗血管生成治疗策略在癌症治疗中得到了很好的描述。贝伐珠单抗和阿柏西普的抗血管生成活性已在伊朗人群中 10 种不同纯度的已建立的原发性口腔鳞状细胞癌 (OSCC) 细胞上进行了研究，旨在寻找最有效的抗血管生成靶向药物。
为了研究和比较贝伐珠单抗和阿柏西普对 10 种原发性 OSCC 细胞血管内皮生长因子 (VEGF) 分泌的影响，通过 ELISA 和 MTT 检测评估细胞增殖和活力。此外，还使用划痕实验研究了细胞迁移。
结果表明，所有原发性癌细胞均显著表达 VEGF。虽然两种药物都显著降低了 VEGF 的分泌，但阿柏西普的效果更为显著。此外，与对照组相比，贝伐珠单抗处理的细胞迁移率较低，而与贝伐珠单抗和对照组相比，阿柏西普处理的细胞迁移率最低。
抗血管生成靶向药物，特别是阿柏西普，可能与常规手术治疗联合用于治疗 OSCC 患者有效。
